Actual Medicinal Product (AMP) Pentasa 1g modified-release tablets (Ferring Pharmaceuticals Ltd)

Stability Information

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes
There are no stability notes available for this medicine.
Provenance

This compatibility recommendation is derived from Pentasa 1g modified-release tablets (Ferring Pharmaceuticals Ltd).

Generic
Mesalazine
Formulation
Mesalazine 1g modified-release tablets
  • Mesalazine
    • Mesalazine 1g modified-release tablets

      • Pentasa 1g modified-release tablets (Ferring Pharmaceuticals Ltd)